Engineered immune cells take aim at Hard-to-Treat cancers
NCT ID NCT04429451
First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This study is testing a new treatment called 4SCAR-PSMA T cells for people whose cancers have a specific marker called PSMA. The therapy involves collecting a patient's own immune cells, modifying them to better recognize and attack cancer cells, and infusing them back. Up to 100 participants with advanced or recurrent PSMA-positive tumors will be enrolled to see if the treatment is safe and can shrink tumors.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- 4SCAR-PSMA T cells (a type of immune cell therapy)
- What this could lead to
- If it works, this could point toward a new treatment option for certain cancers that express PSMA, potentially shrinking tumors or slowing disease progression.
- What could go wrong
- This is an early-phase trial (Phase I/II) with only 100 participants, so results may not apply broadly. Side effects from CAR-T therapy can be severe, including immune reactions and organ damage.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for PSMA POSITIVE TUMORS OR TUMOR TISSUES are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Shenzhen Geno-immune Medical Institute
RECRUITINGShenzhen, Guangdong, 518000, China
More trials for these conditions
Other studies related to the condition(s) this trial covers.